查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1970830

全球人類乳突病毒疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Human Papillomavirus Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 141 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計人類乳突病毒疫苗市場將從 2025 年的 96.6 億美元成長到 2034 年的 210.9 億美元，2026 年至 2034 年的複合年成長率為 9.06%。

隨著免疫接種計畫在已開發經濟體和新興經濟體中日益重要，全球人類乳突病毒（HPV）疫苗市場正經歷加速成長。政府主導的各項措施不斷擴大，民眾對HPV相關癌症的認知不斷提高，以及透過公私合營改善疫苗取得途徑，都推動了疫苗接種率的提升。生物技術的進步，包括耐熱配方和新一代佐劑系統，正在克服低溫運輸限制，提高疫苗效力，並改善資源匱乏地區疫苗宣傳活動的成效。

對更廣泛的人類乳突病毒(HPV)疫苗的持續研究正在改變競爭格局。推動開發涵蓋更多致癌性病毒株的多價疫苗製劑，將顯著增強疫苗策略的長期影響。同時，將人類乳突病毒(HPV)疫苗納入國家免疫規劃，並整合用於監測和合規性的數位化健康平台，正在加強機構的採納。此外，製藥公司正在優先發展可擴展的生產平台，例如重組DNA技術和細胞培養系統，從而降低成本並增加供應。

展望未來，生物製藥公司、診斷公司和公共衛生機構之間的合作將推動HPV預防的綜合辦法。疫苗與人工智慧驅動的流行病學模型、精準公共衛生框架和全球宣傳宣傳活動的整合有望進一步提高疫苗接種率。隨著醫療保健、公平取得和個人化免疫接種方案變得日益重要， 人類乳突病毒(HPV)疫苗市場將繼續擴大，成為全球癌症防治策略的基礎。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球人類乳突病毒疫苗市場：依類型分類

  • 市場分析、洞察與預測
  • 二價
  • 四價
  • 九價

第5章 全球人類乳突病毒疫苗市場：依疾病分類

  • 市場分析、洞察與預測
  • 子宮頸癌
  • 陰道癌及外陰癌
  • 肛門癌
  • 口腔和咽喉（頭頸部）癌
  • 生殖器濕疣

第6章：全球人類乳突病毒疫苗市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院和零售藥局
  • 政府採購承包商
  • 其他

第7章 全球人類乳突病毒疫苗市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Merck & Co. Inc
    • GlaxoSmithKline Plc（GSK）
    • Serum Institute Of India Pvt. Ltd
    • Sanofi Pasteur SA
    • Pfizer Inc
    • Inovio Pharmaceuticals Inc
    • Walvax Biotechnology Co. Ltd
    • Bharat Biotech International Ltd
    • Johnson & Johnson Services Inc
    • Moderna Inc
    • Gilead Sciences Inc
簡介目錄
Product Code: VMR112111434

The Human Papillomavirus Vaccine Market size is expected to reach USD 21.09 Billion in 2034 from USD 9.66 Billion (2025) growing at a CAGR of 9.06% during 2026-2034.

The global human papillomavirus vaccine market is positioned for accelerated growth as immunization programs gain prominence across both developed and emerging economies. Expanding government-led initiatives, rising awareness of HPV-related cancers, and increasing accessibility of vaccines through public-private partnerships are driving adoption rates. Biotechnology advances, including thermostable formulations and next-generation adjuvant systems, are addressing cold-chain limitations and enhancing efficacy, making vaccination campaigns more effective in resource-constrained regions.

Continuous research into broader-spectrum HPV vaccines is reshaping the competitive landscape. The push for multivalent formulations that cover an expanded range of oncogenic strains will significantly boost the long-term impact of vaccination strategies. Meanwhile, integration of HPV vaccines into national immunization schedules, coupled with digital health platforms for monitoring and compliance, is reinforcing systemic adoption. Additionally, pharmaceutical manufacturers are prioritizing scalable production platforms such as recombinant DNA technologies and cell-based systems, allowing for cost reduction and expanded supply availability.

In the future, collaborations between biopharma companies, diagnostic firms, and public health agencies will drive a holistic approach to HPV prevention. The growing convergence of vaccines with AI-driven epidemiological modeling, precision public health frameworks, and global awareness campaigns will intensify uptake. With rising emphasis on preventive healthcare, equitable access, and personalized immunization schedules, the HPV vaccine market will continue to expand as a cornerstone of global cancer control strategies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Bivalent
  • Quadrivalent
  • Nonavalent

By Disease

  • Cervical Cancer
  • Vaginal and Vulvar Cancers
  • Anal Cancer
  • Oropharyngeal (Head and Neck) Cancers
  • Genital Warts

By Distribution Channel

  • Hospitals and Retail Pharmacies
  • Government Suppliers
  • Others

COMPANIES PROFILED

  • Merck Co Inc, GlaxoSmithKline plc GSK, Serum Institute of India Pvt Ltd, Sanofi Pasteur SA, Pfizer Inc, Inovio Pharmaceuticals Inc, Walvax Biotechnology Co Ltd, Bharat Biotech International Ltd, Johnson Johnson Services Inc, Moderna Inc, Gilead Sciences Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Bivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Quadrivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Nonavalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY DISEASE 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Disease
  • 5.2. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Vaginal and Vulvar Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Anal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.5. Oropharyngeal (Head and Neck) Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.6. Genital Warts Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospitals and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Government Suppliers Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.2.1 By Type
    • 7.2.2 By Disease
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.3.1 By Type
    • 7.3.2 By Disease
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.4.1 By Type
    • 7.4.2 By Disease
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.5.1 By Type
    • 7.5.2 By Disease
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.6.1 By Type
    • 7.6.2 By Disease
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HUMAN PAPILLOMAVIRUS VACCINE INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Merck & Co. Inc
    • 9.2.2 GlaxoSmithKline Plc (GSK)
    • 9.2.3 Serum Institute Of India Pvt. Ltd
    • 9.2.4 Sanofi Pasteur SA
    • 9.2.5 Pfizer Inc
    • 9.2.6 Inovio Pharmaceuticals Inc
    • 9.2.7 Walvax Biotechnology Co. Ltd
    • 9.2.8 Bharat Biotech International Ltd
    • 9.2.9 Johnson & Johnson Services Inc
    • 9.2.10 Moderna Inc
    • 9.2.11 Gilead Sciences Inc